O-1 ECONOMIC IMPACT OF LONG-TERM ALBUMIN INFUSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND UNCOMPLICATED ASCITES FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES
Introduction and Objectives: Liver cirrhosis is among the most common liver-related causes of death and is associated with severe complications that entail a major burden for patients and healthcare systems. The ANSWER trial showed that long-term human albumin infusions (LTA) (40g twice/week for two...
Main Authors: | Carlos Terra, Elisabet Viayna, Laura Ayzin, Cristina Fuster, Susana Aceituno, Maria Soler, Claudio Tafla |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268123001163 |
Similar Items
-
ALBUMIN VERSUS STANDARD MEDICAL TREATMENT IN BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS
by: Carlos TERRA, et al.
Published: (2023-09-01) -
Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings
by: Irsan Hasan, et al.
Published: (2024-04-01) -
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
by: Lorenz Balcar, et al.
Published: (2022-08-01) -
Advances in decompensated cirrhosis treatment by human serum albumin
by: ZHANG Chenxi, et al.
Published: (2023-01-01) -
Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study
by: Nicholas Hannah, et al.
Published: (2023-08-01)